Core Viewpoint - Allot Ltd. is conducting a public offering of 5,000,000 ordinary shares priced at $8.00 per share, with an additional option for underwriters to purchase up to 750,000 shares [1][2]. Group 1: Offering Details - The gross proceeds from the offering are expected to be $40.0 million, assuming no exercise of the underwriters' option [2]. - The net proceeds will be used to repay $31.41 million of principal outstanding under the Lynrock Note and the remainder for general corporate purposes [2][3]. - The offering is expected to close on June 26, 2025, subject to customary closing conditions [1]. Group 2: Lynrock Note Conversion - Lynrock has agreed to convert the remaining $8.59 million of principal under the Lynrock Note into 1,249,995 ordinary shares [3]. - Following the repayment and conversion of the Lynrock Note, the company will have no outstanding indebtedness for borrowed money [3]. Group 3: Underwriters and Registration - TD Cowen and William Blair are acting as joint book-running managers, with Needham & Company as lead manager and Northland Capital Markets as co-manager for the offering [4]. - The public offering is made pursuant to an effective shelf registration statement filed with the SEC [5].

Core Viewpoint - Allot Ltd. announced a proposed public offering of its ordinary shares, with all shares being sold by the Company [1]. Group 1: Use of Proceeds - The net proceeds from the public offering are expected to be used to repay $31.41 million of principal outstanding under the Lynrock Note, which has a face value of $40 million, and the remaining balance will be allocated for general corporate purposes [2]. - Lynrock has agreed to convert the remaining $8.59 million of principal outstanding under the Lynrock Note into ordinary shares, and will enter into a lock-up agreement for 75 days following the final prospectus supplement [3]. Group 2: Offering Details - The Company plans to grant underwriters a 30-day option to purchase up to an additional 15% of the ordinary shares sold in the public offering at the public offering price, less underwriting discounts and commissions [4]. - The public offering is being made under an effective shelf registration statement on Form F-3 filed with the SEC, declared effective on April 3, 2025 [5]. Group 3: Company Overview - Allot Ltd. is recognized as a leading global provider of innovative network intelligence and security solutions for service providers and enterprises worldwide [7].

Hong Kong, June 23, 2025 (GLOBE NEWSWIRE) -- Happy City Holdings Limited (Nasdaq: HCHL) (the “Company”), an established all-you-can-eat hotpot restaurant operator in Hong Kong , today announced the pricing of its initial public offering (the “Offering”) of 1,100,000 Class A ordinary shares (the “Class A Ordinary Shares”), at a price of $5.00 per Class A Ordinary Share (the “Offering Price”). The Class A Ordinary Shares are expected to begin trading on the Nasdaq Capital Market on June 24, 2025 under the sym ...

HONG KONG, June 23, 2025 /PRNewswire/ -- QMMM Holdings Limited (NASDAQ: QMMM) (the "Company" or "QMMM"), a digital media advertising, virtual avatar & virtual apparel technology service provider in Hong Kong, today announced the closing of its best efforts public offering of 40,000,000 ordinary shares at a public offering price of $0.20 per ordinary share.Gross proceeds, before deducting placement agent fees and other offering expenses, are expected to be $8 million.Pacific Century Securities LLC and Revere ...

NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Enigmatig Limited (NYSE American: EGG) ("Enigmatig" or the "Company"), an international consultancy firm providing one-stop cross-border licensing solutions and related services, today announced that it has completed its previously announced initial public offering (the "IPO") and the sole bookrunner, on behalf of the underwriters, has exercised the over-allotment opinion in part to purchase an additional 160,000 shares of common stock from the Company at the IPO ...

$4 million upfront with up to an additional $4 million of potential aggregate gross proceeds upon the exercise in full of short-term warrantsDENVER, June 20, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (the “Company” or “SeaStar Medical”) (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, today announced the pricing of a public offering of 6,153,847 shares of the Company’s commo ...

SINGAPORE, June 18, 2025 (GLOBE NEWSWIRE) -- Vantage Corp (NYSE American: VNTG) (“Vantage” or the “Company”), a shipbroking company providing comprehensive services including brokerage, consultancy, and operational support in the tanker market, announced today that the underwriter of its initial public offering (the “Offering”) has fully exercised their over-allotment options to purchase an additional 487,500 Class A Ordinary Shares at the public offering price of $4.00 per share, resulting in additional gr ...

Core Viewpoint - Biomea Fusion, Inc. has announced a public offering of common stock and warrants, aiming to raise approximately $40 million before expenses, with the offering expected to close on June 20, 2025 [1][2]. Group 1: Offering Details - The offering consists of 19,450,000 shares of common stock and accompanying warrants, along with pre-funded warrants for an additional 550,000 shares [1]. - The combined offering price for each share of common stock and accompanying warrant is set at $2.00, while the pre-funded warrant and accompanying warrant are priced at $1.9999 [1]. - Underwriters have a 30-day option to purchase up to an additional 3,000,000 shares and/or warrants at the public offering price [1]. Group 2: Financial Proceeds - The gross proceeds from the offering are expected to be approximately $40 million, excluding any additional shares or warrants purchased by underwriters [2]. - The offering is subject to customary closing conditions and is anticipated to close on June 20, 2025 [2]. Group 3: Management and Regulatory Information - Jefferies is acting as the sole book-running manager for the offering [3]. - The securities are being offered under an effective shelf registration statement previously filed with the SEC [3].

HANOVER, Md., June 17, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (the “Company”), a clinical-stage pharmaceutical company developing Next Generation Cancer (NGC) therapies, today announced the pricing of a public offering of 28,000,000 shares of common stock (or pre-funded warrants in lieu thereof), together with common warrants to purchase up to 28,000,000 shares of common stock at a combined public offering price of $0.25 per share (or pre-funded warrant in lieu thereof) and a ...

GLEN ALLEN, Va., June 17, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the pricing of its "reasonable best efforts" public offering for the purchase and sale of 11,100,000 shares of common stock of the Company (or common stock equivalents in lieu thereof), together with Series D warrants to purchase ...